Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Glogal COVID-19 Vaccine Development

  • Pfizer and BioNTech to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply
  • Potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval by regulatory authorities, and then rapidly scale up capacity to produce hundreds of millions of doses in 2021
  • BioNTech will contribute multiple mRNA vaccine candidates as part of its BNT162 COVID-19 vaccine program, which are expected to enter human testing in April 2020
  • Pfizer will contribute its leading global vaccine clinical research and development, regulatory, manufacturing and distribution infrastructure and capabilities
  • BioNTech will receive an upfront payment of $185 million, including an equity investment of approximately $113 million, and be eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million

Continue reading

Pfizer Advances Battle Against COVID-19 on Multiple Fronts

    • Anti-viral compounds show activity against SARS-CoV-2 in preclinical screening
    • Pfizer and BioNTech enter into collaboration agreement to co-develop potential COVID-19 vaccine Company shares additional data and analysis of azithromycin
    • Launch of two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2
    • Pfizer explores studies of JAK inhibitor tofacitinib in patients with COVID-19-related pneumonia

Continue reading

Kauffman Fellows and Venture Capitalists “Meet” to Discuss COVID-19 Impacts

Over 250 Kauffman Fellows and VCs from all continents held a two day Zoom Conference last week to examine the effect of COVID on investment practices.  The Kauffman Fellows Program is a network of over 500 VCs and entrepreneurs.  Our Dr. Patricia Beckmann, a Kauffman Fellow, participated in the brainstorming session to encourage sharing and best practices. Continue reading

Flinn Biopreneur Spotlight: Humabiologics

Humabiologics, a regenerative medicine startup company founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers is a member of the 2020 Flinn Foundation Bioscience Entrepreneurship Program co-hort and now part of a statewide community of Flinn Biopreneurs.Continue reading